Loading
Miguel Martín is the founder of the Spanish breast cancer group GEICAM and a leader of adjuvant chemotherapy trials.
Miguel Martín is Head of Medical Oncology at Hospital General Universitario Gregorio Marañón in Madrid and Chairman of GEICAM, the Spanish breast cancer research group he founded. His specialisms are breast cancer, adjuvant chemotherapy and cooperative group trials. He led trials of adjuvant docetaxel-based regimens, including BCIRG 001, the New England Journal of Medicine trial of adjuvant docetaxel for node-positive breast cancer. He has also been involved in CDK4/6 inhibitor trials including PALLAS and monarchE, which tested palbociclib and abemaciclib. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Adjuvant docetaxel for node-positive breast cancer (BCIRG 001) | NEJM | 2005 |
| monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer | Journal of Clinical Oncology | 2020 |
| NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer | New England Journal of Medicine | 2024 |
Ribociclib is a second adjuvant CDK4/6 option, and the only one with data in node-negative stage II disease. Roughly 3 in 100 patients avoid a relapse or death at three years, so the decision depends heavily on individual risk, tolerance of a three-year oral drug, and cost. Whether the benefit persists after treatment ends, as it did with abemaciclib, needs longer follow-up.
Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.
Shares Hospital General Universitario Gregorio Marañón, GEICAM Spanish Breast Cancer Group, Triple-negative breast cancer (TNBC).
Shares monarchE, monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer, Abemaciclib, HR-positive / HER2-negative breast cancer.
Shares NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer, Palbociclib, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares PALLAS & PENELOPE-B, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares Palbociclib, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.